ELCO Management’s Lineage Cell Therapeutics LCTX Stock Holding History

ELCO Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.6K	Sell	15,000 -5,500	-27%	-$7.6K	0.01%	173
2026 Q1	$32.4K	Hold	20,500	–	–	0.02%	169
2025 Q4	$34.2K	Buy	20,500 +500	+3%	+$865	0.02%	156
2025 Q3	$33.8K	Buy	20,000 +3,800	+23%	+$4.5K	0.02%	162
2025 Q2	$14.7K	Buy	16,200 +1,300	+9%	+$771	0.01%	156
2025 Q1	$6.73K	Hold	14,900	–	–	﹤0.01%	155
2024 Q4	$7.49K	Buy	14,900 +2,900	+24%	+$2.13K	﹤0.01%	158
2024 Q3	$10.9K	Hold	12,000	–	–	0.01%	163
2024 Q2	$12K	Hold	12,000	–	–	0.01%	156
2024 Q1	$17.8K	Hold	12,000	–	–	0.01%	154
2023 Q4	$13.1K	Hold	12,000	–	–	0.01%	142
2023 Q3	$14.2K	Hold	12,000	–	–	0.01%	135
2023 Q2	$16.9K	Hold	12,000	–	–	0.01%	128
2023 Q1	$18K	Hold	12,000	–	–	0.01%	136
2022 Q4	$16.7K	Hold	12,000	–	–	0.01%	137
2022 Q3	$14K	Buy	+12,000	New	+$17.6K	0.01%	139

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

ELCO Management's LCTX Position: Q2 2026 in Review

ELCO Management reduced its Lineage Cell Therapeutics (LCTX) stake by 27% in Q2 2026, selling an estimated $7.6K and leaving 15,000 shares worth $19.6K. The position accounts for 0.01% of the portfolio, ranked #173.

ELCO Management first reported a position in LCTX in Q3 2022 and has held it in 16 quarters since. The position peaked at $34.2K in Q4 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

ELCO Management held 15,000 shares of Lineage Cell Therapeutics worth $19.6K as of Q2 2026.
ELCO Management sold 5,500 Lineage Cell Therapeutics shares in Q2 2026, an estimated $7.6K.
Lineage Cell Therapeutics made up 0.01% of ELCO Management's portfolio in Q2 2026, its #173 holding.
ELCO Management first reported a position in Lineage Cell Therapeutics in Q3 2022 and has held it in 16 quarters since.
ELCO Management's Lineage Cell Therapeutics position peaked at $34.2K in Q4 2025.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on ELCO Management's 13F filing for Q2 2026, filed 11 Aug 2026.